Upgrade to SI Premium - Free Trial

MiNK Therapeutics (INKT)

11.78 +0.14 (1.20%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/13/26)

Latest Headlines

Form S-8 MiNK Therapeutics, Inc. August 13, 2026 4:34 PM - SEC Filing Form 10-Q MiNK Therapeutics, Inc. For: Jun 30 August 13, 2026 4:31 PM - SEC Filing Form 8-K MiNK Therapeutics, Inc. For: Aug 13 August 13, 2026 7:41 AM - SEC Filing MiNK Therapeutics reports Q2 2026 results and Phase 2 trial data August 13, 2026 7:30 AM - StreetInsider MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury August 13, 2026 7:30 AM - StreetInsider MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates August 6, 2026 8:19 AM - Globe NewsWire Agenus posts Q2 revenue of $34.5M, plans Phase 3 colon cancer trial August 6, 2026 7:30 AM - StreetInsider Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer August 6, 2026 7:30 AM - BizWire Form 8-K MiNK Therapeutics, Inc. For: Jun 17 June 23, 2026 10:10 AM - SEC Filing Full Article List